EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

Karam Mounzer iD, Jihad Slim iD, Moti Ramgopal, Malcolm Hedgcock iD, Mark Bloch, Jorge Santana iD, Keith Aizen iD, Xu Zhang iD, Peter Sklar iD, Jairo M Montezuma-Rusca, Sorana Segal-Maurer iD

Open Forum Infectious Diseases · 30.10.2025 · 12 (11)

DOI: 10.1093/ofid/ofaf615 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.10.2025. Verfasst von Karam Mounzer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1. At 48 weeks, BIC + LEN (at either LEN dose) was highly effective at maintaining virologic suppression and was well tolerated.

Schlagwörter

Stichwörter der Autor:innen

HIV-1bictegravirclinical trialcomplex antiretroviral regimenslenacapavir

Autor:innen und Institutionen

  • Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA.
  • New York Medical College, Valhalla, New York, USA.
  • Midway Immunology and Research Center, Fort Pierce, Florida, USA.
  • Spectrum Health, Vancouver, British Columbia, Canada.
  • Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia.
  • School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.

ORCID-Profile: Karam Mounzer, Jihad Slim, Malcolm Hedgcock, Jorge Santana, Keith Aizen, Xu Zhang, Peter Sklar, Sorana Segal-Maurer

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Mounzer, K., Slim, J., Ramgopal, M., Hedgcock, M., Bloch, M., Santana, J., Aizen, K., Zhang, X., Sklar, P., Montezuma-Rusca, J. M., & Segal-Maurer, S. (2025). Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases, 12(11). https://doi.org/10.1093/ofid/ofaf615

Vancouver

Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, et al. Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases. 2025;12(11). doi:10.1093/ofid/ofaf615

BibTeX
@article{Mounzer2025,
  author = {Mounzer, Karam and Slim, Jihad and Ramgopal, Moti and Hedgcock, Malcolm and Bloch, Mark and Santana, Jorge and Aizen, Keith and Zhang, Xu and Sklar, Peter and Montezuma-Rusca, Jairo M and Segal-Maurer, Sorana},
  title = {Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {11},
  doi = {10.1093/ofid/ofaf615}
}
Kostenlos starten →